


ChIP-seq technology and applications

D. Puthier, C. Rioualen, J. van Helden
Galaxy Workshop — Cuernavaca, 2017

ChIP-Seq principle




- Used to analyze, at the level of whole genomes:
 - transcription factor binding locations
 - histone modifications



ChIP-seq for 13 TFs in mouse ES cells


Integration of External Signaling Pathways with the Core Transcriptional Network in Embryonic Stem Cells

Xi Chen,^{1,2,6} Han Xu,^{3,6} Ping Yuan,¹ Fang Fang,^{1,2} Mikael Huss,⁴ Vinsensius B. Vega,³ Eleanor Wong,⁵ Yuriy L. Orlov,⁴ Weiwei Zhang,^{1,2} Jianming Jiang,^{1,2} Yui-Han Loh,^{1,2} Hock Chuan Yeo,⁴ Zhen Xuan Yeo,⁴ Vipin Narang,³ Kunde Ramamoorthy Govindarajan,³ Bernard Leong,³ Atif Shahab,³ Yijun Ruan,⁵ Guillaume Bourque,³ Wing-Kin Sung,³ Neil D. Clarke,⁴ Chia-Lin Wei,^{5,*} and Huck-Hui Ng^{1,2,*}



ChIP-Seq analysis in brief

- Fragments (typically ~300bp) cover the region of interest + some pieces on both side.
- We only sequence a short read on one or both extremities
- **The binding site is thus generally not in our reads !**
- Solutions
 - Bioinfo read extension
 - Bioinfo: read shifting
 - Experiment: Exo-ChIP (digest flanks between sequencing).




Aligned reads

Binding profile

Binding Peak

Epigenetic modifications of histones



Dataset used

- Estrogen-receptor (ESR1) is a key factor in **breast cancer development**.
- Goal of the study: understand the dependency of ESR1 binding on presence of cofactors, in particular GATA3, which is mutated in breast cancers.
- Approaches: GATA3 silencing (siRNA), ChIP-seq on ESR1 in WT vs. siGATA3 conditions, chromatin profiling.

Research

GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility

Vasiliki Theodorou,¹ Rory Stark,² Suraj Menon,² and Jason S. Carroll^{1,3,4}

¹Nuclear Receptor Transcription Lab, ²Bioinformatics Core, Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Cambridge CB2 0RE, United Kingdom; ³Department of Oncology, University of Cambridge, Cambridge CB2 0XZ, United Kingdom